COMPANY

Azevan Pharmaceuticals Inc

HQ: Bethlehem, PA source · azevan.com ↗ · Mid-Atlantic

Keywords: Huntington's disease intermittent explosive disorder depression autism Aggressive Behavior in Fragile X Syndome Irritable Mood PTSD Fear Anxiety traumatic brain injury post traumatic stress disorder SRX246 SRX251

Location: Bethlehem, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

9Trials (company is sponsor)24NIH grants

Timeline

2026-03 Trial start Phase 2: Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome source ↗
Feb 3, 2017 Trial start Phase 1: Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans source ↗
2016-12 Trial start Phase 2: Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD source ↗
May 10, 2016 Trial start Phase 2: Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease source ↗
2014-05 Trial start Phase 1/Phase 2: Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder source ↗
2010-03 Trial start Phase 1: Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers source ↗
2009-05 Trial start Phase 1: Study of SRX246 Capsules in Healthy Adult Volunteers source ↗
2007-09 Trial start Phase 1: Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers source ↗
2007-04 Trial start Phase 1: Safety Study of SRX251 Capsules in Healthy Female Volunteers source ↗

Upcoming milestones

2027-03 (ESTIMATED) · Phase 2 · Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome · NCT07328529

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07328529	Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome	Phase 2	Not yet recruiting	2026-03	2027-03 (estimated)
NCT02055638	Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder	Phase 1/Phase 2	Completed	2014-05	2016-05 (actual)
NCT02507284	Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease	Phase 2	Completed	May 10, 2016	Sep 10, 2018 (actual)
NCT02733614	Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD	Phase 2	Terminated	2016-12	2020-10 (actual)
NCT02922166	Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans	Phase 1	Unknown status (ClinicalTrials.gov)	Feb 3, 2017	May 10, 2019 (actual)
NCT01088932	Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers	Phase 1	Completed	2010-03	2010-06 (actual)
NCT00910455	Study of SRX246 Capsules in Healthy Adult Volunteers	Phase 1	Completed	2009-05	2009-09 (actual)
NCT00532467	Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers	Phase 1	Completed	2007-09	2008-02 (actual)
NCT00461370	Safety Study of SRX251 Capsules in Healthy Female Volunteers	Phase 1	Completed	2007-04	2007-08 (actual)

NIH awards 24

Annual award amounts. Total $16.4M.

Sep 16, 2020 NIH award 2R44NS090616-05 FY2020: $3,190,881 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Advancing SRX246 to Commeri source ↗
May 1, 2019 NIH award 1R43NS110343-01A1 FY2019: $501,472 awarded for that fiscal year; activity R43 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A New Drug for the Treatmen source ↗
Feb 1, 2018 NIH award 5U44NS090616-04 FY2018: $764,163 awarded for that fiscal year; activity U44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Tolerability of SRX246 in Hun source ↗
Feb 27, 2017 NIH award 3U44NS090616-03S1 FY2017: $61,234 awarded for that fiscal year; activity U44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Tolerability of SRX246 in Hu source ↗
Feb 8, 2017 NIH award 5U44NS090616-03 FY2017: $1,480,173 awarded for that fiscal year; activity U44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Tolerability of SRX246 in H source ↗
Mar 21, 2016 NIH award 4U44NS090616-02 FY2016: $2,214,354 awarded for that fiscal year; activity U44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Tolerability of SRX246 in H source ↗
Aug 10, 2015 NIH award 1U44NS090616-01A1 FY2015: $1,115,185 awarded for that fiscal year; activity U44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Tolerability of SRX246 in source ↗
Jul 3, 2013 NIH award 5R44MH087001-04 FY2013: $598,813 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. New Drugs for Stress-related source ↗
Jul 16, 2012 NIH award 5R44MH087001-03 FY2012: $595,262 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. New Drugs for Stress-related source ↗
Sep 20, 2011 NIH award 3R44MH087001-02S1 FY2011: $115,000 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. New Drugs for Stress-relate source ↗
Jul 13, 2011 NIH award 4R44MH087001-02 FY2011: $600,000 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. New Drugs for Stress-related source ↗
May 24, 2011 NIH award 1R41MH093049-01A1 FY2011: $141,071 awarded for that fiscal year; activity R41 (STTR); PI SIMON, NEAL GORDON; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Screening New Therapeutics for source ↗
May 1, 2010 NIH award 1R44MH087001-01A1 FY2010: $349,195 awarded for that fiscal year; activity R44 (SBIR); PI BROWNSTEIN, MICHAEL J; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. New Drugs for Stress-relate source ↗
Sep 30, 2009 NIH award 3R44MH063663-08S1 FY2009: $226,385 awarded for that fiscal year; activity R44 (SBIR); PI DAMIANO, EVE MARIE; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A Potential New Drug for Depre source ↗
Aug 11, 2009 NIH award 5R44MH063663-08 FY2009: $795,315 awarded for that fiscal year; activity R44 (SBIR); PI DAMIANO, EVE MARIE; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A Potential New Drug for Depress source ↗
Aug 30, 2008 NIH award 5R44MH063663-07 FY2008: $797,078 awarded for that fiscal year; activity R44 (SBIR); PI KOPPEL, GARY A; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A Potential New Drug for Depression source ↗
Aug 29, 2007 NIH award 2R44MH063663-06 FY2007: $801,007 awarded for that fiscal year; activity R44 (SBIR); PI KOPPEL, GARY A; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A Potential New Drug for Depression source ↗
Aug 21, 2006 NIH award 5R44MH063663-05 FY2006: $449,093 awarded for that fiscal year; activity R44 (SBIR); PI KOPPEL, GARY A; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A New Drug for Depression source ↗
Nov 7, 2005 NIH award 6R44MH063663-04 FY2005: $449,073 awarded for that fiscal year; activity R44 (SBIR); PI KOPPEL, GARY A; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A New Drug for Depression source ↗
Aug 31, 2004 NIH award 2R44MH063663-02A1 FY2004: $449,054 awarded for that fiscal year; activity R44 (SBIR); PI KOPPEL, GARY A; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A New Drug for Depression source ↗
Jun 18, 2003 NIH award 5R42HD037290-03 FY2003: $248,665 awarded for that fiscal year; activity R42 (STTR); PI SIMON, NEAL G; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Treating Self-Abuse in Autism and Men source ↗
Jul 1, 2002 NIH award 2R42HD037290-02A1 FY2002: $250,019 awarded for that fiscal year; activity R42 (STTR); PI SIMON, NEAL G; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. Treating Self-Abuse in Autism and M source ↗
Feb 13, 2002 NIH award 1R41MH063663-01A1 FY2002: $100,000 awarded for that fiscal year; activity R41 (STTR); PI SIMON, NEAL G; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. A New Drug for Depression source ↗
Apr 14, 2000 NIH award 1R41HD037290-01 FY2000: $100,000 awarded for that fiscal year; activity R41 (STTR); PI SIMON, NEAL G; recipient as written: AZEVAN PHARMACEUTICALS, INC., BETHLEHEM, PA. TREATING SELF-ABUSE IN AUTISM AND MEN source ↗